Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676090 | 0.93 | LMNA (0.64) | ALDH1A1POLBL3MBTL1LMNAMEN1 | |
| SCHEMBL6680388 | 0.91 | ALDH1A1 (0.61) | ALDH1A1POLBL3MBTL1LMNAMEN1 | |
| SCHEMBL7541541 | 0.91 | ALDH1A1 (0.61) | ALDH1A1POLBL3MBTL1LMNAMEN1 | |
| SCHEMBL6674434 | 0.90 | ALDH1A1 (0.60) | ALDH1A1POLBL3MBTL1LMNAMEN1 | |
| SCHEMBL6675755 | 0.87 | ALDH1A1 (0.64) | ALDH1A1POLBL3MBTL1LMNAMEN1 | |
| SCHEMBL6678286 | 0.87 | ALDH1A1 (0.57) | ALDH1A1POLBL3MBTL1LMNAMEN1 | |
| SCHEMBL6678901 | 0.86 | LMNA (0.60) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL6680004 | 0.86 | ALDH1A1 (0.58) | ALDH1A1POLBLMNAMEN1KMT2A | |
| SCHEMBL6675545 | 0.85 | ALDH1A1 (0.58) | ALDH1A1POLBL3MBTL1LMNAMEN1 | |
| SCHEMBL7534865 | 0.85 | ALDH1A1 (0.55) | ALDH1A1POLBL3MBTL1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | claimed |
| EP-1005453-B1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS | TULARIK INC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6388131-B2 | Benzenesulfonamide compounds, which encompasses the compound batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene) | TULARIK, INC. | 2002-05-14 | — | — | US | disclosed |
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | disclosed |
| US-6284923-B1 | BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS | TULARIK INC | 2001-09-04 | — | — | US | disclosed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | ALDH1A1 1173/4885POLB 638/4885L3MBTL1 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.